Accuracy Appoints Jack Goldstein, Ph.D. to Board of Directors
5/26/2010 7:56:07 AM
SUNNYVALE, Calif., May 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the appointment of Jack Goldstein, Ph.D. as a member of the company's Board of Directors, effective immediately.
Dr. Goldstein is currently an independent consultant who most recently served as President and Chief Operating Officer of Chiron Corporation from 2004 to 2006, and from 2002 to 2004 he served as President of Chiron Corporation's Blood Testing Division. Prior to that, from 2000 to 2002, he was a general partner at Windamere Venture Partners and from 1997 to 2001 Dr. Goldstein was President and Chief Executive Officer at Applied Imaging Corporation. Dr. Goldstein serves on the board of directors of OncoGenex Pharmaceuticals, Inc. and Orasure Technologies, Inc. and previously served on the boards of Applied Imaging Corporation, Immucor and Illumina, Inc.
"We are delighted to have Jack Goldstein joining the Board, and welcome his expertise, commitment and enthusiasm," said Euan S. Thomson, Ph.D., president and chief executive officer at Accuray. "Dr. Goldstein has dedicated over 20 years of his professional career to the medical device and pharmaceutical industries and Accuray will benefit from his extensive knowledge and experience."
Dr. Goldstein's breadth of leadership extends to marketing, sales, manufacturing, research and development in the healthcare industry, specifically within the pharmaceuticals and diagnostic fields. Dr. Goldstein has successfully run multi-billion dollar companies, built effective sales and marketing organizations, and developed and launched start-up enterprises.
"It is an honor to join Accuray's distinguished Board of Directors," said Dr. Goldstein. "As the market leader in radiosurgery, Accuray has achieved a global track record of excellence and I'm excited to be a part of this dynamic, growing organization."
It is expected that Dr. Goldstein will serve on the Compensation Committee of the Board of Directors.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 80,000 treatments worldwide and currently 196 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to qualitative management experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on May 6, 2010, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated